STOCK TITAN

Bausch Health Companies Inc Stock Price, News & Analysis

BHC NYSE

Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Bausch Health Companies Inc. (BHC) delivers innovative healthcare solutions across gastroenterology, dermatology, and eye health through brands like Bausch + Lomb and Salix Pharmaceuticals. This page provides investors and industry professionals with a comprehensive repository of official company announcements and market-relevant updates.

Key resources include: earnings reports, regulatory filings, product launch announcements, and partnership developments. All content is sourced directly from BHC’s verified communications to ensure accuracy and timeliness.

Regularly updated with press releases spanning therapeutic advancements, financial results, and operational milestones. Bookmark this page to monitor BHC’s strategic initiatives within the global pharmaceutical landscape.

Rhea-AI Summary

Bausch Health Companies will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. Key executives, including Joseph C. Papa (Chairman and CEO), Sam Eldessouky (SVP), and Arthur J. Shannon (SVP of Investor Relations), will present. Investors can access a live webcast and audio archive on the company’s Investor Relations page. Bausch Health focuses on pharmaceuticals, medical devices, and over-the-counter products, particularly in eye health, gastroenterology, and dermatology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced on August 31, 2020, a plan to reduce its debt by $100 million through the redemption of senior notes. The company will redeem $100 million of its 5.875% Senior Notes due September 30, 2020, using cash generated from operations. An irrevocable notice of redemption will be issued to the record holders of these notes. Bausch Health aims to strengthen its financial position and continues to focus on advancing global health through its healthcare products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
Rhea-AI Summary

Bausch Health's subsidiary, Bausch + Lomb, has received approval from Australia's Therapeutic Goods Administration (TGA) for the BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses. This product is expected to be available to select practitioners in Australia by Q4 2020, with a nationwide launch planned for early 2021. This approval complements Bausch + Lomb's existing contact lens offerings and aligns with the company’s expansion strategy, which includes launches in Japan and the United States, as well as further expansions in Canada and Hong Kong.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
Rhea-AI Summary

Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary

Bausch Health announced the approval of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses by Health Canada. These lenses incorporate Advanced MoistureSeal® Technology and ComfortFeel Technology, ensuring a high level of comfort and eye health for up to 16 hours. They will be available to select practitioners in Canada starting Q4 2020, with a full launch expected in early 2021. This innovation enhances Bausch + Lomb's existing product portfolio, aiming to improve patient experience in eye care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary

Bausch Health reported revenues of $1.664 billion for Q2 2020, a 23% decline from Q2 2019, largely due to the COVID-19 pandemic.

GAAP net loss was $326 million, compared to a $171 million loss in the same quarter last year.

The company has narrowed its full-year revenue guidance to $7.80 - $8.00 billion and Adjusted EBITDA to $3.15 - $3.30 billion.

Despite challenges, Bausch Health is focused on market share growth and launching new products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
Rhea-AI Summary

Bausch Health Companies Inc. (BHC) announced its plan to spin off its eye health business, creating an independent entity named Bausch + Lomb - NewCo. This strategic move aims to enhance focus on two distinct business segments: a dedicated eye health company and a diversified pharmaceutical firm specializing in gastroenterology, aesthetics/dermatology, and neurology. The spinoff is expected to improve financial transparency and unlock shareholder value. Bausch + Lomb - NewCo reported $3.7 billion in revenue for 2019, while BHC's revenue was $4.9 billion, with plans to report separate financials starting Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none
-
Rhea-AI Summary

Bausch Health (NYSE/TSX: BHC) has resolved a legacy investigation by the SEC concerning its past relationship with Philidor Rx and certain accounting practices from 2014-2015. The settlement, which involves a $45 million civil penalty for negligence-based charges, resolves all SEC claims without admission of guilt. The company has undergone significant management changes, with a new Board of Directors credited for remedial actions. CEO Joseph C. Papa emphasized that this resolution is a crucial step in the company's transformation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) and Ortho Dermatologics announced nine recipients of the 2020 Aspire Higher scholarship program, aimed at supporting students affected by dermatologic conditions. Each recipient will receive up to $10,000 for their education. The program has awarded a total of $738,000 to 51 students since its inception in 2013. The recipients were selected from nearly 220 applications, showcasing their challenges and successes in education. To learn more, visit AspireHigherScholarships.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) will release its second-quarter 2020 financial results on August 6, 2020, at 8:00 a.m. EDT. The company will host a conference call and live webcast to discuss the results and provide a business update. Interested parties can access the materials on the Investor Relations section of Bausch Health's website prior to the call. A replay of the call will be available until August 20, 2020, with specific dial-in information provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

The current stock price of Bausch Health Companies (BHC) is $6.31 as of July 18, 2025.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately 2.4B.
Bausch Health Companies Inc

NYSE:BHC

BHC Rankings

BHC Stock Data

2.45B
323.52M
11.31%
70.94%
1.75%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Canada
QUEBEC